Latest Regenerative medicine Stories
Can stem cells provide an answer to the perplexing question of how to ensure long-term survival of transplanted kidneys? The results of a new Phase 1 clinical trial say maybe so. Details of the trial, conducted by researchers at Leiden University Medical Center, The Netherlands, are published in the current issue of STEM CELLS Translational Medicine. Durham, NC (PRWEB) February 07, 2013 Kidney transplants have long been the treatment of choice for many patients with end-stage renal...
Johns Hopkins Medicine Researchers at Johns Hopkins have devised a way to detect whether cells previously transplanted into a living animal are alive or dead, an innovation they say is likely to speed the development of cell replacement therapies for conditions such as liver failure and type 1 diabetes. As reported in the March issue of Nature Materials, the study used nanoscale pH sensors and magnetic resonance imaging (MRI) machines to tell if liver cells injected into mice survived over...
WINSTON-SALEM, N.C., Feb. 5, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that A. Brian Davis, Chief Financial Officer and Vice President, Finance of Tengion, will present at the upcoming BIO CEO & Investor Conference on Tuesday, February 12, 2013, at 10:30 a.m. EST in New York City. A live audio webcast of the presentation can be accessed at http://www.veracast.com/webcasts/bio/ceoinvestor2013/23210244.cfm or under...
New research has shown the presence of a disease affecting small blood vessels, known as microangiopathy, in the bone marrow of diabetic patients. While it is well known that microangiopathy is the cause of renal damage, blindness and heart attacks in patients with diabetes, this is the first time that a reduction of the smallest blood vessels has been shown in bone marrow, the tissue contained inside the bones and the main source of stem cells. These precious cells not only replace old...
SAN DIEGO, Jan. 31, 2013 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that the Company was granted 20 patents worldwide in 2012, eight U.S. and twelve foreign. These patents bolster the Company's already strong proprietary position for its ground-breaking diabetes product, VC-01, as well as other applications of its broad...
WINSTON-SALEM, N.C., Jan. 30, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced advances for its two lead programs, the Neo-Urinary Conduit(TM) and Neo-Kidney Augment(TM). "We look forward to successfully implanting the remaining three patients in the ongoing Phase 1 trial for the Neo-Urinary Conduit by the end of this quarter. Following the implantation of patient seven, we have begun to transfer the surgical procedure to...
A new study from Boston University School of Medicine (BUSM) shows that tissues derived from induced pluripotent stem (iPS) cells in an experimental model were not rejected when transplanted back into genetically identical recipients. The study, published online in Cell Stem Cell, demonstrates the potential of utilizing iPS cells to develop cell types that could offer treatment for a wide range of conditions, including diabetes, liver and lung diseases, without the barrier of immune...
CLEVELAND, Jan. 28, 2013 /PRNewswire-USNewswire/ -- Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease announced today that Paul Resnick, M.D., M.B.A., has joined the company as Vice President of Business Development. Dr. Resnick brings more than 25 years of healthcare and business development experience to the role. In this position, Dr. Resnick's efforts will be to drive business...
NEW YORK, Jan. 22, 2013 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announced that on January 17, 2013 the Company received a notice of allowance regarding its U.S. Patent Application Serial No. 13/323,030 entitled "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells." The allowed claims apply to IntelliCell's proprietary method for deriving blood vessel originated vascular cells from adipose (fat) tissue by use of...
Raises hope for developing new therapies for many diseases Scientists at the Texas Biomedical Research Institute have for the first time demonstrated that baboon embryonic stem cells can be programmed to completely restore a severely damaged artery. These early results show promise for eventually developing stem cell therapies to restore human tissues or organs damaged by age or disease. "We first cultured the stem cells in petri dishes under special conditions to make them...
